In sporadic CRC lesions, KRAS mutations are inversely associated to the oncogenic BRAFV600E mutation [33, 44–46], suggesting that each mutation can induce similar cellular effects and signal through the same pathway. Here, KRAS is linked to colorectal carcinoma.